PPIs and Gut Health: Long-Term Omeprazole Explained

Medically reviewed and written by Dr Zeeshan Afzal (MBBS), Medical Officer at Welzo. Last updated: 3 August 2026.

Omeprazole is one of the most widely dispensed medicines in the UK, and for millions of people it is exactly the right drug. But the questions people ask us about omeprazole long term effects — after two, five or ten years on a daily capsule — deserve honest, evidence-based answers rather than scare stories. Because stomach acid is the first gatekeeper of the digestive system, suppressing it for years has knock-on effects on nutrient absorption, infection risk and the microbial community explored across our gut health range and our complete guide to gut health in the UK. If you are researching how to protect your digestion while taking a proton pump inhibitor (PPI), the evidence below covers what is proven, what is uncertain, and what is simply not true — alongside supportive options many people ask about, including clinically studied probiotics, Akkermansia muciniphila, modified citrus pectin powder, ultra-purity berberine and ultra-purity TUDCA.

Important: never stop a prescribed PPI without speaking to your GP or pharmacist. For some conditions, stopping causes more harm than continuing.

Table of contents

• What omeprazole is and how it works
• What counts as "long-term" omeprazole use?
• Omeprazole long term effects: what the evidence actually shows
• Risk summary table: strength of evidence
• PPIs and the gut microbiome
• Rebound acid hypersecretion: why stopping is hard
• How to reduce risk if you need to stay on omeprazole
• How to come off omeprazole safely
• Drug interactions worth knowing about
• Red flags: when to see a doctor urgently
• Frequently asked questions
• References

What omeprazole is and how it works

Omeprazole belongs to a class of drugs called proton pump inhibitors. It works by irreversibly blocking the hydrogen-potassium ATPase enzyme — the "proton pump" — on the parietal cells that line the stomach. These pumps are the final common step in acid production, so switching them off is highly effective: a standard dose can reduce daily gastric acid output by around 60–90% depending on dose and timing.

Chemical structure of omeprazole. Image: Wikimedia Commons, public domain (PD-chem).

How PPIs differ from antacids and H2 blockers

• Antacids (e.g. calcium carbonate, alginates) neutralise acid already present. They work in minutes and wear off in an hour or two.
• H2 receptor antagonists (e.g. famotidine) block one of the three signals that stimulate acid production. Moderately effective, tolerance develops within weeks.
• PPIs (omeprazole, lansoprazole, esomeprazole, pantoprazole, rabeprazole) block the pump itself. Because new pumps take roughly two days to be manufactured, acid suppression far outlasts the drug's 90-minute half-life.

That potency is exactly why omeprazole heals oesophagitis and ulcers so reliably — and also why long-term use has downstream consequences.

Why stomach acid matters beyond digestion

Gastric acid does four jobs that become relevant when you suppress it for years:

1. Antimicrobial barrier. A pH below 4 kills the majority of swallowed bacteria before they reach the intestine.
2. Protein digestion. Acid activates pepsinogen into pepsin and denatures dietary protein.
3. Mineral solubilisation. Non-haem iron, calcium carbonate and magnesium all require an acidic environment to be efficiently freed from food.
4. Vitamin B12 release. Acid and pepsin cleave B12 from the dietary protein it is bound to, allowing intrinsic factor to carry it to the ileum.

If you want a deeper dive into what happens when acid runs too low for any reason, see our guide to low stomach acid symptoms and the related evidence on betaine HCl supplements in the UK.

What counts as "long-term" omeprazole use?

There is no single definition, but in the research literature and in UK prescribing practice the thresholds that matter are:

• Over-the-counter omeprazole: the NHS advises not taking it for longer than two weeks without seeing a GP.
• Standard prescribed course: typically 4–8 weeks for reflux, gastritis or ulcer healing.
• "Long-term" in safety studies: usually defined as continuous use beyond 12 months, which is when most of the adverse associations start to appear in observational data.
• Indefinite maintenance: appropriate and evidence-supported for Barrett's oesophagus, severe erosive oesophagitis, Zollinger-Ellison syndrome, and NSAID ulcer prophylaxis in high-risk patients.

The clinically important point is that a large share of long-term prescriptions were never reviewed. Published estimates suggest 30–50% of patients on PPIs are taking them for an inappropriate indication, dose or duration. That is the group for whom a medication review with a GP is most worthwhile — not people with a genuine ongoing need.

Omeprazole long term effects: what the evidence actually shows

Most of what you read online about PPI harms comes from observational studies. These are useful for generating hypotheses but poor at proving cause and effect, because people prescribed long-term PPIs are on average older, sicker and on more medications than those who are not. The single most informative dataset is the COMPASS randomised controlled trial, which randomised 17,598 participants to pantoprazole 40 mg daily or placebo and followed them for a median of just over three years, collecting safety data every six months.

Its finding was reassuring: across pneumonia, fracture, chronic kidney disease, dementia, diabetes, gastric atrophy, chronic lung disease, cancer and death, there was no significant excess in the PPI group. The one exception was enteric infection, which was modestly higher (odds ratio 1.33, 95% CI 1.01–1.75).

The human digestive system. Acid suppression in the stomach has knock-on effects further down the tract. Image: Wikimedia Commons, public domain.

Nutrient absorption

Vitamin B12

This is the best-established nutritional consequence. A large Kaiser Permanente case-control study comparing 25,956 people with new B12 deficiency against 184,199 controls found that two or more years of PPI use was associated with a 65% increase in the odds of deficiency (OR 1.65, 95% CI 1.58–1.73), with a dose-response relationship. Higher daily doses carried higher risk.

Not every study agrees — some meta-analyses find no significant difference in serum B12 — but the mechanism is coherent, and it is reasonable for anyone on omeprazole beyond about three years to have B12 checked, particularly if they are vegetarian, vegan, over 65, or also taking metformin. Our guide to a gut health blood test explains which markers are worth requesting.

Magnesium

PPI-induced hypomagnesaemia is uncommon but can be serious, causing muscle cramps, tremor, palpitations, arrhythmias and seizures. The MHRA issued a Drug Safety Update on this in 2012 and advises considering a baseline magnesium measurement plus periodic monitoring in people expected to be on prolonged treatment — especially those also taking digoxin or diuretics, which independently lower magnesium. Reported cases typically emerge after months to years, not weeks, and resolve on withdrawal plus replacement.

If you already use magnesium, note that the form matters for digestive tolerance — see our comparison of magnesium for constipation.

Iron and calcium

Non-haem iron (the form in plant foods and most supplements) needs acid to be reduced from ferric to ferrous form. Long-term acid suppression can therefore contribute to iron deficiency, and some people find oral iron both less effective and harder on the gut — see iron supplements and constipation. Calcium carbonate absorption is similarly acid-dependent, which is the proposed mechanism linking PPIs to reduced bone density.

Gut infections and Clostridioides difficile

This is the one signal that survived randomisation. Losing the acid barrier means more live bacteria reach the colon. Observational studies have consistently linked PPIs to C. difficile infection, salmonella, campylobacter and travellers' diarrhoea; COMPASS confirmed a modest but real excess of enteric infections overall. In that trial C. difficile cases were roughly twice as frequent on pantoprazole (nine versus four), though with only 13 events in total this did not reach statistical significance.

Scanning electron micrograph of Clostridioides difficile. Image: CDC Public Health Image Library via Wikimedia Commons, public domain.

The practical implication is greatest around antibiotic courses and foreign travel. Our guides to probiotics for C. diff, probiotics after antibiotics, Saccharomyces boulardii and travellers' diarrhoea probiotics cover the strain-specific evidence.

Bone health and fracture risk

The MHRA has advised since 2012 that there is a modest increased fracture risk with PPIs, particularly at high doses and durations beyond a year, with meta-analyses suggesting risk elevated roughly 10–40% above baseline. UK prescribing guidance recommends assessing osteoporosis risk and ensuring adequate calcium and vitamin D intake in anyone on long-term treatment.

Counterbalancing this, COMPASS found no excess fractures over three years of randomised treatment. The most reasonable interpretation: any true effect is small, concentrated in people who already have osteoporosis risk factors, and manageable through bone-health basics rather than by stopping a needed medicine.

Kidney health

A widely cited analysis of the Atherosclerosis Risk in Communities cohort published in JAMA Internal Medicine reported an association between PPI use and incident chronic kidney disease. Acute interstitial nephritis is an accepted, if rare, idiosyncratic reaction to PPIs and provides a plausible mechanism. However, the randomised COMPASS data found no increase in chronic kidney disease, so residual confounding remains the likeliest explanation for much of the observational signal. Unexplained new kidney impairment in someone on a PPI still warrants review.

Dementia

Early German cohort studies suggested a link, and laboratory work showing PPIs affect amyloid-beta processing made it biologically plausible. Subsequent larger analyses have not replicated it, and the randomised COMPASS data found no increase in dementia. On current evidence there is no good reason to believe omeprazole causes dementia.

Stomach lining changes, gastrin and polyps

Suppressing acid raises the hormone gastrin, which has a trophic effect on enterochromaffin-like (ECL) cells in the stomach lining. Pooled data across ten studies covering more than 27,000 participants suggest maintenance PPI therapy beyond six months is associated with an approximately threefold increase in ECL cell hyperplasia. In practice this manifests most often as benign fundic gland polyps, found incidentally at endoscopy, which typically regress after stopping the drug. Progression to gastric neuroendocrine tumours is very rare in people without Zollinger-Ellison syndrome.

The relationship with gastric cancer is more contested and confounded by Helicobacter pylori status. If you have not been tested, our guides to H. pylori infection and H. pylori testing in the UK explain why eradication matters before committing to years of acid suppression. Related conditions are covered in gastritis and stomach ulcers.

Risk summary table: strength of evidence

PPIs and the gut microbiome

This is where the gut-health conversation has moved in the last decade. In a landmark analysis published in Gut, researchers examined stool samples across three large Dutch cohorts, 211 of whose participants were taking a PPI at the time of sampling. PPI use was associated with a significant reduction in Shannon diversity and altered abundance of around 20% of all bacterial taxa.

The characteristic pattern was an invasion of oral bacteria into the lower gut — the genus Rothia was dramatically over-represented — alongside increases in Enterococcus, Streptococcus, Staphylococcus and Escherichia coli. Strikingly, the authors concluded that at population level the effect of PPIs on the microbiome was more pronounced than that of antibiotics or other commonly used drugs. Independent work confirms the same oral-to-gut translocation signature, driven by loss of the gastric acid checkpoint.

Escherichia coli at approximately 10,000× magnification. Image: USDA Agricultural Research Service via Wikimedia Commons, public domain.

Why this matters practically: reduced diversity is the same direction of travel seen in gut dysbiosis, and it predicts poorer colonisation resistance against pathogens. It may also reduce production of short-chain fatty acids such as butyrate, which feed colonocytes and support gut barrier function. Higher acid suppression is also one recognised contributor to small intestinal bacterial overgrowth (SIBO), which can present confusingly as worsening bloating and reflux on a drug meant to fix reflux.

If you want to establish a baseline, our comparison of gut microbiome tests in the UK outlines what these can and cannot tell you, and microbiome diversity explains why the number of species matters more than any single "good" bacterium.

Rebound acid hypersecretion: why stopping is hard

Perhaps the most under-discussed of all omeprazole long term effects is what happens when you stop. In a double-blind, placebo-controlled trial, 120 healthy volunteers with no acid-related disease were randomised either to 12 weeks of placebo, or to eight weeks of esomeprazole 40 mg followed by four weeks of placebo. In the weeks after withdrawal, 44% of the PPI group reported clinically relevant heartburn, acid regurgitation or dyspepsia, compared with 15% of the placebo group.

These were people who had never had reflux. The symptoms were created by the drug, via a rebound surge in acid secretion from the gastrin-driven expansion of parietal cell mass. This matters enormously in real life, because a patient who stops omeprazole, feels awful within a week and restarts it reasonably concludes they "still need it" — when what they actually experienced was a self-limiting withdrawal effect. Understanding this is the single biggest predictor of successfully coming off.

How to reduce risk if you need to stay on omeprazole

Plenty of people should stay on a PPI. The aim then is the lowest effective dose plus sensible mitigation.

Monitoring worth discussing with your GP

• Vitamin B12 — after around three years of continuous use, or sooner with risk factors.
• Serum magnesium — at baseline and periodically if on diuretics, digoxin or with unexplained cramps.
• Ferritin and full blood count — if fatigued, breathless or a heavy menstrual bleeder.
• Vitamin D and fracture risk assessment — particularly post-menopause or over 70.
• Annual medication review — the single most valuable intervention. Ask specifically: "Do I still need this, at this dose?"

Diet, timing and lifestyle

• Take omeprazole 30–60 minutes before your first meal; it only inactivates pumps that are actively secreting, so timing meaningfully changes efficacy.
• Eat protein with meals containing plant iron, and pair with vitamin C to improve absorption without acid.
• Weight loss around the abdomen, avoiding late meals, raising the head of the bed and reducing alcohol all reduce the reflux burden itself — see acid reflux supplements and strategies in the UK.
• Avoid unnecessary NSAIDs, which are a common reason for needing a PPI in the first place — see ibuprofen and stomach damage.

Supporting the microbiome

Given the documented diversity loss, a food-first strategy makes sense: aim for a wide range of plants each week, plenty of high-fibre foods, and regular fermented foods. Our overview of the best foods for gut health is the place to start.

For supplementation, the evidence is strain-specific rather than generic. Practical questions are covered in how to choose a probiotic, when to take probiotics and whether probiotics survive stomach acid — a question that becomes less of an obstacle, not more, when acid is suppressed. Mucosal support options people commonly ask about include zinc carnosine, slippery elm and aloe vera for the gut. Always tell your GP or pharmacist what you are taking alongside prescribed medication.

How to come off omeprazole safely

Only with your prescriber, and only if the original indication has resolved. Deprescribing is generally not appropriate for Barrett's oesophagus, severe erosive oesophagitis, a history of bleeding ulcer, or ongoing high-dose NSAID or antiplatelet therapy.

Stomach, colon and rectum. Reduced gastric acid allows more swallowed bacteria to survive into the lower bowel. Image: Wikimedia Commons, public domain.

The usual approach

1. Confirm the indication has resolved — ulcer healed, H. pylori eradicated, NSAID stopped.
2. Halve the dose for 2–4 weeks (for example 20 mg to 10 mg daily).
3. Move to alternate days, or to on-demand use only when symptoms occur, for a further 2–4 weeks.
4. Stop, with an antacid or alginate available for breakthrough symptoms.
5. Expect a bumpy fortnight. Rebound symptoms usually peak in weeks 1–2 and settle by weeks 4–8. Knowing this in advance is what stops people restarting unnecessarily.

Some people find that reflux symptoms after stopping were never acid-driven at all, but functional or motility-related. If bloating and wind dominate, trapped wind relief and foods that cause bloating may be more relevant than acid control. Tracking stool form using the Bristol stool chart during a taper gives a useful objective record to bring to your GP.

Drug interactions worth knowing about

• Clopidogrel: omeprazole and esomeprazole inhibit CYP2C19, which activates clopidogrel. UK guidance advises avoiding this combination; pantoprazole or lansoprazole are usually preferred alternatives.
• Methotrexate: high-dose methotrexate clearance may be reduced.
• Antifungals and HIV medicines: ketoconazole, itraconazole and atazanavir need acid for absorption and may become less effective.
• Diuretics and digoxin: additive risk of low magnesium.
• Citalopram, phenytoin, warfarin: may require monitoring due to shared metabolic pathways.
• Metformin: not a direct interaction, but compounds B12 depletion risk — see metformin stomach side effects.

Red flags: when to see a doctor urgently

Acid suppression can mask symptoms of more serious disease. Contact your GP promptly, or seek urgent care, if you have:

• Difficulty or pain on swallowing, or a sensation of food sticking
• Unintentional weight loss
• Vomiting blood, or vomit resembling coffee grounds
• Black, tarry stools
• Persistent vomiting, or a new lump in the abdomen
• New severe dyspepsia over the age of 55
• Iron deficiency anaemia without an obvious cause

Our guide on when to see a GP about stomach symptoms covers this in more detail, alongside bowel cancer screening in the UK.

Frequently asked questions

What are the long term effects of taking omeprazole every day?

The best-supported long-term effects are reduced vitamin B12 absorption, occasional low magnesium, a modest increase in gut infections including C. difficile, and measurable shifts in the gut microbiome towards lower diversity. Associations with fractures and kidney disease exist in observational data but were not confirmed in a large three-year randomised trial. Dementia links have not been replicated.

Is it safe to take omeprazole for years?

For people with a clear ongoing indication — Barrett's oesophagus, severe oesophagitis, ulcer prophylaxis on NSAIDs — the benefits generally outweigh the risks, and randomised data support safety over at least three years. The problem is not long-term use itself but long-term use without a current indication. An annual review with your GP is the right safeguard.

Does omeprazole damage your gut microbiome?

It measurably changes it. Research published in Gut found PPI users had reduced bacterial diversity, changes in around 20% of taxa, and an increase in oral bacteria colonising the lower gut. The authors judged the population-level effect larger than that of antibiotics. Whether this causes symptoms varies between individuals.

Can long-term omeprazole cause B12 deficiency?

Yes, this is the most consistently reported nutritional effect. A study of over 25,000 people with B12 deficiency found two or more years of PPI use associated with 65% higher odds of deficiency, with higher doses carrying higher risk. Ask your GP about testing if you have been on it more than three years.

Why do my reflux symptoms get worse when I stop omeprazole?

This is rebound acid hypersecretion. In a placebo-controlled trial, 44% of healthy volunteers with no prior reflux developed heartburn, regurgitation or indigestion after just eight weeks of a PPI was withdrawn, versus 15% on placebo. It is temporary — usually settling within four to eight weeks — and is best managed by tapering rather than stopping abruptly.

Should I take a probiotic while on omeprazole?

There is a reasonable rationale, given the documented diversity loss and raised infection risk, particularly around antibiotic courses or travel. Benefits are strain-specific rather than universal. Discuss with your pharmacist, especially if you are immunocompromised, and see our overview of probiotic side effects.

Can omeprazole cause SIBO or bloating?

Acid suppression is one recognised contributing factor to small intestinal bacterial overgrowth, because gastric acid normally limits how many bacteria survive passage into the small bowel. Some people on long-term PPIs report increasing bloating and wind. If this describes you, discuss SIBO testing with your GP.

Does omeprazole increase the risk of stomach cancer?

Evidence here is mixed and heavily confounded by H. pylori status, which is itself the dominant risk factor. Long-term PPI use does raise gastrin and is associated with benign fundic gland polyps and ECL cell hyperplasia. Current UK practice is to test for and eradicate H. pylori where appropriate rather than to withhold necessary acid suppression.

What is the safest alternative to long-term omeprazole?

There is no universally "safer" drug — the right answer depends on why you are taking it. Options a GP may consider include a lower PPI dose, on-demand rather than daily use, switching to an H2 blocker such as famotidine, or alginate preparations for postprandial reflux. Weight management, meal timing and alcohol reduction address the underlying mechanics.

How long does it take to recover gut health after stopping omeprazole?

Acid secretion normalises within weeks, and studies tracking the microbiome show the PPI-associated changes are largely reversible after discontinuation. Rebuilding diversity is a food-driven process over months rather than days; the practical levers are plant variety, fibre and fermented foods, as covered in our guide to increasing gut bacteria diversity.

References

1. NHS. Omeprazole — medicines information.
2. Medicines and Healthcare products Regulatory Agency. Proton pump inhibitors in long-term use: reports of hypomagnesaemia. Drug Safety Update, 2012.
3. Medicines and Healthcare products Regulatory Agency. Proton pump inhibitors in long-term use: increased risk of fracture. Drug Safety Update, 2012.
4. National Institute for Health and Care Excellence. Clinical Knowledge Summary: Dyspepsia — proven GORD.
5. National Institute for Health and Care Excellence. CG184: Gastro-oesophageal reflux disease and dyspepsia in adults.
6. Moayyedi P, Eikelboom JW, Bosch J, et al. Safety of proton pump inhibitors based on a large, multi-year, randomized trial of patients receiving rivaroxaban or aspirin. Gastroenterology. 2019;157(3):682–691.
7. Imhann F, Bonder MJ, Vich Vila A, et al. Proton pump inhibitors affect the gut microbiome. Gut. 2016;65(5):740–748.
8. Reimer C, Søndergaard B, Hilsted L, Bytzer P. Proton-pump inhibitor therapy induces acid-related symptoms in healthy volunteers after withdrawal of therapy. Gastroenterology. 2009;137(1):80–87.
9. Freedberg DE, Kim LS, Yang YX. The risks and benefits of long-term use of proton pump inhibitors: expert review and best practice advice from the American Gastroenterological Association. Gastroenterology. 2017;152(4):706–715.
10. Targownik LE, Fisher DA, Saini SD. AGA Clinical Practice Update on de-prescribing of proton pump inhibitors: expert review. Gastroenterology. 2022;162(4):1334–1342.
11. Lam JR, Schneider JL, Zhao W, Corley DA. Proton pump inhibitor and histamine 2 receptor antagonist use and vitamin B12 deficiency. JAMA. 2013;310(22):2435–2442.
12. Lazarus B, Chen Y, Wilson FP, et al. Proton pump inhibitor use and the risk of chronic kidney disease. JAMA Internal Medicine. 2016;176(2):238–246.
13. Chaudhry M, Elahi M, Bukhari SHA, et al. Long-term proton pump inhibitor use and the risk of kidney disease, dementia, and fractures: a systematic review. Cureus. 2025.
14. Zhang J, et al. Proton pump inhibitors and oral–gut microbiota: from mechanism to clinical significance. 2024.
15. The association of proton pump inhibitors and inflammatory bowel disease from the perspective of gut microbiota perturbation. npj Biofilms and Microbiomes. 2025.
16. Kieboom BCT, et al. Hypomagnesaemia associated with long-term use of proton pump inhibitors. Gastroenterology Report.
17. Ahmed S, et al. Effects of long-term proton pump inhibitor use on serum electrolytes and vitamin levels: a quasi-experimental study. Cureus. 2025.

About the author

Dr Zeeshan Afzal (MBBS) is a practising medical doctor and Medical Officer at Welzo, where he writes and clinically reviews content across digestive health, metabolic health and preventative medicine. This article was written and reviewed against UK regulatory guidance (MHRA, NICE) and peer-reviewed primary literature current to August 2026.

Medical disclaimer: This article is for information only and does not constitute medical advice, diagnosis or treatment. Omeprazole is a prescription and pharmacy medicine; do not start, stop, change the dose of, or substitute any prescribed medication without first consulting your GP, pharmacist or specialist. If you experience red-flag symptoms such as vomiting blood, black stools, difficulty swallowing or unexplained weight loss, seek medical attention urgently or call 111.